CoChat

Remimazolam: First Approval

Keam, Susan J. · 2020 · Drugs

The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.

Abstract

Remimazolam (Anerem ® in Japan; ByFavo™ in the USA; Aptimyda™ in the EU) is an ultra-short-acting intravenous (IV) benzodiazepine sedative/anesthetic being developed by PAION AG in conjunction with a number of commercial partners for use in anesthesia and procedural sedation. Remimazolam was approved on 23 January 2020 in Japan for use in general anesthesia in adult patients. Remimazolam is also undergoing regulatory assessment in South Korea for this indication and for use in procedural sedation in the USA, the EU and China. This article summarises the major milestones in the development of remimazolam for this first approval for the induction and maintenance of general anaesthesia, and its potential upcoming approvals in general anaesthesia and procedural sedation.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40265-020-01299-8

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 18 references

Research works printed but not linked: 2

  1. Acacia Pharma Group plc. Acacia Pharma announces brief extension of FDA review period for NDA for BYFAVO™ [media release]. 12 Mar 2020. https://www.acaciapharma.com/.
  2. PAION AG. PAION announces submission of the marketing authorization application for remimazolam in procedural sedation to the European Medicines Agency [media release]. 20 Nov 2019. https://www.paion.com/.

Cited by

See all 217

Metadata

Authors
Keam, S. J.
Affiliations
Springer Nature (New Zealand) (NZ)
Corresponding author
Keam, Susan J.
Venue
Drugs
Published
2020-04
Volume
80
Issue
6
Pages
625-633
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W3015486573
Cited by
188
References
19
Citations by year
2026: 26 · 2025: 39 · 2024: 46 · 2023: 29 · 2022: 29 · 2021: 18 · 2020: 1
FWCI
5.83
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
  • Health Sciences › Veterinary › Small Animals › Veterinary Pharmacology and Anesthesia
Keywords
remimazolam, general anesthesia, procedural sedation, drug approval, regulatory evaluation, drug development milestones
MeSH terms
Anesthesia, General, Animals, Benzodiazepines, Colonoscopy, Humans, Hypnotics and Sedatives, Molecular Conformation, Drug Approval, Anesthetics, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Remimazolam: First Approval. https://app.cochat.ai/papers/10.1007/s40265-020-01299-8
The paper
Keam, S. J. (2020). Remimazolam: First Approval. Drugs. https://doi.org/10.1007/s40265-020-01299-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.